Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDR1 | Q08345 | 2/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2380937 | 0.84 | DRD2 (0.42) | GRIN2BMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL2379743 | 0.84 | CHRNB2 (0.43) | ALDH1A1LMNASMN1; SMN2OPRL1OPRM1 | |
| SCHEMBL2381743 | 0.83 | CYP2D6 (0.53) | ALDH1A1MAPK1CYP2D6TSHRCYP3A4 | |
| SCHEMBL2381188 | 0.81 | MEN1 (0.39) | MEN1KMT2AALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL2381186 | 0.81 | MEN1 (0.39) | MEN1KMT2AALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL2311622 | 0.80 | ATM (0.57) | MEN1KMT2AALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL2380597 | 0.80 | PARP1 (0.47) | MEN1KMT2AALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL2381083 | 0.80 | PARP1 (0.47) | MEN1KMT2AALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL2314391 | 0.78 | SIGMAR1 (0.51) | ALDH1A1OPRL1 | |
| SCHEMBL2308063 | 0.78 | OPRM1 (0.47) | MEN1KMT2AALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8815869-B2 | Lactam acetamides as calcium channel blockers | ABBVIE INC. (US) | 2014-08-26 | — | — | US | disclosed |
| WO-2011115813-A1 | LACTAM ACETAMIDES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2011-09-22 | — | — | WO | disclosed |
| US-20110230459-A1 | LACTAM ACETAMIDES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230459-A1 | LACTAM ACETAMIDES AS CALCIUM CHANNEL BLOCKERS | CACNA1E, CACNA1D, CACNA1S | DDR1 2191/4885GRIN2B 248/4885MEN1 470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.